The authors have outlined how authors can recreate their dataset in the methods and materials section. The articles used for this study are outlined in the MS and SI files.

Introduction {#sec004}
============

Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is one of the most common diseases prevalent in old men. The prevalence of BPH among men in their 50s and 60s is 50% rising to 90% by the age of 80s and beyond based on autopsy findings \[[@pone.0203479.ref001], [@pone.0203479.ref002]\].

Medical treatment including alpha-blockers and 5 alpha-reductase inhibitors (5ARI) take possession of the primary treatment strategy in patients with BPH/LUTS \[[@pone.0203479.ref003], [@pone.0203479.ref004]\]. The combination of alpha-blockers and 5ARI improved LUTS and maximal urinary flow rate (Qmax)\[[@pone.0203479.ref002], [@pone.0203479.ref003]\]. In earlier 2000s, two important randomized controlled studies (RCTs) including the Medical Therapy of Prostatic Symptoms (MTOPS) \[[@pone.0203479.ref005]\] and the Combination of Avodart® and Tamsulosin (CombAT) study \[[@pone.0203479.ref006]\] established the superiority of long-term combination therapy over alpha-blocker monotherapy or placebo in the treatment of patients with BPH/LUTS. Furthermore, treatment using 5ARIs showed a positive effect including decreased prostate volume, improved International Prostate Symptom Score (IPSS), improved Qmax, decreased risk of acute urinary retention (AUR) and decreased operative procedures related with BPH/LUTS \[[@pone.0203479.ref005], [@pone.0203479.ref007]--[@pone.0203479.ref009]\]. Moreover, several systematic reviews showed that 5ARI, especially, finasteride improves LUTS by long-term treatment, however, combination treatment with alpha blockers showed better improvement than finasteride monotherapy \[[@pone.0203479.ref010], [@pone.0203479.ref011]\].

However, recent studies reported persistent complications of 5ARI including erectile dysfunction (ED) and decreased libido even after discontinuation of 5ARI \[[@pone.0203479.ref012]--[@pone.0203479.ref014]\]. Similarly, treatment with finasteride 1mg for androgenic alopecia has shown persistent ED after its withdrawal \[[@pone.0203479.ref015]\]. Currently, FDA recommends a change in 5ARI labeling to include the possibility of persistent adverse events even after discontinuation in several post-marketing studies \[[@pone.0203479.ref016], [@pone.0203479.ref017]\]. Two recent reviews of 5ARI are warning clinicians to inform their patients fully regarding the adverse events of erectile dysfunction, decreased libido, gynecomastia, and anxiety \[[@pone.0203479.ref018], [@pone.0203479.ref019]\]. Moreover, this 5ARI advisory was issued again about the possible risks for suicidal attempts and depression in many recent observational studies \[[@pone.0203479.ref020]\].

Evidence supports the efficacy of 5ARI treatment when combined with alpha-blockers. Several reviews and meta-analyses were limited to only adverse events. Therefore, we have provided an update on the clinical efficacy and adverse events in an effort to develop a rational therapeutic strategy using 5ARI in BPH/LUTS.

Methods {#sec005}
=======

The systematic review with meta-analysis and meta-regression were conducted according to the guidelines provided by the PRISMA guidelines ([S1 Text](#pone.0203479.s001){ref-type="supplementary-material"}).

Inclusion criteria {#sec006}
------------------

This meta-analysis has inclusion criteria as randomized controlled clinical trials (RCTs) with 5ARI and placebo, disease indication of BPH/LUTS, and types of measure has to include at least one of followings: prostate specific antigen (PSA), prostate volume (PV), International Prostate Symptom Score (IPPS), post-void residual urine (PVR), voiding symptoms of IPSS (Voiding IPSS), maximum urinary flow rate (Qmax), and adverse events (AEs).

Searching strategies {#sec007}
--------------------

Based on the PICO (population, intervention, control, and outcomes) process, the following strategies were used: P (patients with symptomatic BPH); I (daily or regular maintenance treatment with 5ARI without any other treatment); C (comparing measured effect size with placebo group); and O (PSA, PV, IPSS, and Qmax). A MEDLINE search from 1966 to March 3, 2017 was performed using specific MeSH headings, including prostatic hyperplasia, lower urinary tract symptoms and 5 alpha-reductase inhibitors, dutasteride, and finasteride. Supplementary terms included dutasteride and finasteride. For natural headings, placebo, dutasteride and finasteride were included. A similar strategy was used for Cochrane collaboration and Embase ([S2 Fig](#pone.0203479.s007){ref-type="supplementary-material"} and [S3 Fig](#pone.0203479.s008){ref-type="supplementary-material"}). Detailed inclusion criteria for the final data extraction in the meta-analysis were: 1) reported outcomes of at least one of the variables included PSA, PV, IPSS, voiding IPSS, PVR, Qmax or adverse events; 2) daily 5ARI treatment; 3) indication for 5ARI use confined to BPH; 4) intention-to-treat analysis with placebo-controlled RCTs.

Data extraction strategies {#sec008}
--------------------------

After merging all the search studies (n = 1312) from MEDLINE, Cochrane collaboration and Embase, duplicate studies (n = 605) were filtered ([Fig 1](#pone.0203479.g001){ref-type="fig"}). A total of 707 studies were screened by title, and a total of 245 studies involving unrelated topics were excluded. A total of 462 studies were screened by abstract and additionally, a total of 306 studies were excluded. Initial screening was performed by JHK and HYS. A total of 156 studies were reviewed for full text. Two authors (JHK and HYS) independently performed screening and full-text assessment, and all disagreements about final inclusion were reviewed by all authors. Data extraction was performed by independent fashion using standardized data extraction form.

![PRISMA flow diagram.](pone.0203479.g001){#pone.0203479.g001}

Assessment of methodological and reporting bias in included studies {#sec009}
-------------------------------------------------------------------

Cochrane collaboration tools including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting were used to assess the risk of methodological bias. Egger's linear regression test was conducted to assess the publication bias.

Statistical analysis {#sec010}
--------------------

The effect of continuous outcomes was summarized as the standardized mean difference (SMD), which was estimated as the difference between the mean change in the treatment and placebo groups divided by the pooled standard deviation (SD). The unreported SDs were estimated from the reported ranges, p-values, standard errors, and sample sizes as described by Hozo, et al.\[[@pone.0203479.ref021]\] The SMD was interpreted as Cohen's d: an SMD of 0.2 \~0.5 was considered small, an SMD of 0.5 to 0.8 moderate, and an SMD over 0.8 as a large effect \[[@pone.0203479.ref022]\].

The SMD exceeding 0.5 represented a clinically meaningful result. To identify the effect of placebo on the continuous outcomes, the ratio of means (ROM), which was a measure of relative change compared with the baseline, was used\[[@pone.0203479.ref023]\]. Binary outcomes were determined by estimating the odds ratio (OR) and 95% confidence interval (CI) using the Mantel-Haenszel methods.

To combine the results of individual studies, a meta-analysis was conducted based on the random effects model as described by DerSimonian and Laird using inverse variance weighting \[[@pone.0203479.ref024]\]. We pre-specified the type of medicine (finasteride, dutasteride, and 5ARI) as the stratified variable based on the assumption that the impact of the treatment varied by the type of medicine. The heterogeneity between studies was assessed for each outcome using I^2^ measure of inconsistency \[[@pone.0203479.ref025]\]. An I^2^ of 25--49% was interpreted as low heterogeneity, 50--74% was moderate, and high when it was greater than 75% \[[@pone.0203479.ref026]\]. Publication bias was examined by generating a funnel plot and performing the Egger's asymmetry test.

Potential source of heterogeneity was investigated via cumulative meta-analysis (including sequential studies according to the publication year) and influential meta-analysis (deriving the pooled estimates by omitting one study at a time). The meta-regression analyses were performed using the publication year and follow-up duration to determine the related effect of the ROM in the placebo group.

Two-sided p value of \<0.05 was considered as statistically significant and all the analyses were performed using R (version 3.4.1; The R Foundation for Statistical Computing, Vienna, Austria).

Results {#sec011}
=======

Study inclusion {#sec012}
---------------

A total of 42 studies were included in this meta-analysis, involving a total of 37449 patients (treatment group: 18587, placebo group: 19162)([Table 1](#pone.0203479.t001){ref-type="table"} and [Fig 1](#pone.0203479.g001){ref-type="fig"}). Five studies were excluded in the final analysis due to insufficient data. A total of 37 studies were finally included in the meta-analysis, involving a total of 23395 patients (treatment group: 11392, placebo group: 12003).

10.1371/journal.pone.0203479.t001

###### Characteristics of all studies included in meta-analysis.

![](pone.0203479.t001){#pone.0203479.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                   Country                                          No. of patients   Mean age(year)                                                                                                               Subject Description                                    Symptom of BPH   Experimental description                                                                                                                                                                                                         
  ----------------------------- ------------------------------------------------ ----------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------- -------------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------- --- --- --- --------------------------------- ---------- ----
  Beisland                      European Urology                                 1992              NA                                                                                                                           94                                                     88               60                         60     Qmax\<15mL/s                                                                                                                          1   0   0   Finasteride                       5          6

  Gormley                       The New England Journal of Medicine              1992              USA, Canada                                                                                                                  297                                                    300              64                         64     Qmax\<15mL/s, voided volume\>150mL                                                                                                    1   0   0   Finasteride                       5          12

  Kirby                         British Journal of Urology                       1992              UK                                                                                                                           31                                                     21               64.4                       64.4   Qmax\<15mL/s, voided volume\>150mL, detrusor pressure during voiding\>50cmH2O2                                                        1   1   0   Finasteride                       5          3

  Stoner                        The Journal of Urology                           1992              USA                                                                                                                          18                                                     25               63.9                       63.9   Enlarged prostate gland of greater than 30cc                                                                                          1   0   1   Finasteride                       5          6

  Tammela                       The Journal of Urology                           1993              Finland                                                                                                                      19                                                     17               65                         65     Qmax\<15mL/s, voided volume\>150mL                                                                                                    1   1   0   Finasteride                       5          6

  Tempany                       The Prostate                                     1993              USA                                                                                                                          12                                                     8                NA                         NA     NA                                                                                                                                    1   0   0   Finasteride                       1 or 5     12

  The finasteride study group   The Prostate                                     1993              Australia, Belgium, Brazil, France, Italy, Mexico, Netherlands, New Zealand, Portugal, Spain, Swizerland, Germany, UK, USA   246                                                    255              66                         66     Qmax\<15mL/s, PV\>30cm^3^                                                                                                             1   0   1   Finasteride                       5          12

  Stoner                        UROLOGY                                          1994              USA                                                                                                                          291                                                    299              64                         64     Qmax\<15mL/s, voided volume\>150mL                                                                                                    1   0   0   Finasteride                       5          12

  International study           242                                              254               66                                                                                                                           66                                                                                                                                                                                                                                                                                                       

  Andersen                      UROLOGY                                          1995              Scandinavian countries(Denmark, Finland, Iceland, Norway, Sweden)                                                            347                                                    346              65.5                       65.5   Qmax5-15mLs, PSA≤10ng/mL, PVR≤150cc                                                                                                   1   0   0   Finasteride                       5          24

  Tammela                       The Journal of Urology                           1995              Finland                                                                                                                      12                                                     15               65                         65     Qmax\<15mL/s, voided volume\>150mL                                                                                                    1   1   0   Finasteride                       5          6

  Yu                            Journal of the Formosan Medical Association      1995              Taiwan                                                                                                                       24                                                     22               66.4                       65.2   NA                                                                                                                                    1   0   0   Finasteride                       5          6

  Lepor                         The New England Journal of Medicine              1996              USA                                                                                                                          305                                                    310              65                         65     AUA\>8, Qmax4-15mL/s, voided volume\>125mL                                                                                            1   0   0   Finasteride                       5          13

  Nickel                        Canadian Medical Association                     1996              Canada                                                                                                                       310                                                    305              63                         63.5   Qmax5-15mLs, voided volume\>150mL, PVR≤150cc, PSA\<10ng/mL                                                                            1   0   0   Finasteride                       5          24

  Habib                         Clinical Endocrinology                           1997              Scotland                                                                                                                     19                                                     9                68.7                       66.7   NA                                                                                                                                    1   0   0   Finasteride                       5          3

  Lepor                         The Journal of Urology                           1998              USA                                                                                                                          44                                                     39               62.5                       62.5   Qmax4-15mL/s, voided volume≥125mL, PVR≤300mL, AUA-SI score≥8                                                                          0   0   0   Finasteride                       5          13

  Marberger                     UROLOGY                                          1998              USA                                                                                                                          1450                                                   1452             63                         63.4   Qmax5-15mL/s, voided volume\>150mL                                                                                                    1   0   0   Finasteride                       5          24

  McConnell                     The New England Journal of Medicine              1998              USA                                                                                                                          1524                                                   1516             64                         64     Qmax≤15mL/s, voided volume\>150mL                                                                                                     1   0   0   Finasteride                       5          48

  Pannek                        The Journal of Urology                           1998              USA                                                                                                                          26                                                     14               65                         64     IPSS\>9, PSA≤10ng/mL                                                                                                                  0   0   0   Finasteride                       5          6

  Abrams                        The Journal of Urology                           1999              USA                                                                                                                          69                                                     37               68.1                       67.4   NA                                                                                                                                    0   0   0   Finasteride                       5          9

  Lukkarinen                    Annales Chirurgiae et Gynaecologiae              1999              Finland                                                                                                                      33                                                     31               65                         65     Boyarsky\<15mL/s, PV\>30cc                                                                                                            1   0   0   Finasteride                       5          24

  Schafer                       UROLOGY                                          1999              Germany, Finland, UK, Sweden, Netherland, Denmark, Portugal, USA                                                             81                                                     40               68.1                       NA     PSA\<10ng/mL                                                                                                                          1   1   0   Finasteride                       5          12

  Feneley                       Prostate cancer and prostatic diseases           2000              UK, Netherland                                                                                                               18                                                     9                67.5                       67.5   BPH/BOO                                                                                                                               1   1   0   Finasteride                       NA         6

  Isotalo                       British Journal of Urology                       2001              Finland                                                                                                                      29                                                     19               71                         71     NA                                                                                                                                    1   0   1   Finasteride                       5          18

  Espana                        BJU International                                2002              Spain                                                                                                                        30                                                     10               66.7                       69.5   Qmax≤15mL/s, IPSS\>7, PVR\<150mL, tPSA\<20ng/mL                                                                                       1   0   0   Finasteride                       NA         9

  Haggstrom                     Scandinavian Journal of Urology and Nephrology   2002              Sweden                                                                                                                       13                                                     15               NA                         NA     NA                                                                                                                                    0   0   0   Finasteride                       5          3

  Roehrborn                     UROLOGY                                          2002              Global study                                                                                                                 2167                                                   2158             66.5                       66.1   Qmax≤15mL/s, PSA≥1.5ng/mL, PV≥30cc, AUA-SI score≥12                                                                                   1   0   0   Dutasteride                       0.5        24

  Kirby                         UROLOGY                                          2003              Europe                                                                                                                       239                                                    253              63                         64     Qmax5-15mLs, voided volume≥150mL, IPSS≥12, Prostate volume nearest 5g                                                                 1   0   0   Finasteride                       5          13

  McConnell                     The New England Journal of Medicine              2003              NA                                                                                                                           89                                                     128              62.6                       62.5   Qmax4-15mL/s, voided volume≥125mL, AUA-SI score 8--35                                                                                 1   0   0   Finasteride                       5          54

  Roehrborn                     The Journal of Urology                           2004              USA                                                                                                                          1524                                                   1516             64                         63.9   Qmax≤15mL/s, voided volume\>150mL                                                                                                     1   0   0   Finasteride                       5          48

  Crawford                      The Journal of Urology                           2006              NA                                                                                                                           NA                                                     737              \-                         62.5   Qmax4-15mL/s, AUA-SI score\>8, voided volume≥125mL                                                                                    1   0   0   Finasteride                       5          54

  Gittelman                     The Journal of Urology                           2006              NA                                                                                                                           2167                                                   2158             65.8                       65.5   Qmax\>15mL/s, AUA_SI\>12, PV\>30cc, PSA1.5-10ng/mL                                                                                    1   0   0   Dutasteride                       0.5        48

  Kaplan                        The Journal of Urology                           2006              USA                                                                                                                          232                                                    250              61                         60.5   AUA8-35, Qmax4-15mL/s, voided volume\>125mL, TPV\<25                                                                                  1   0   1   Finasteride                       5          54

  281                           274                                              61.8              62.4                                                                                                                         AUA8-35, Qmax4-15mL/s, voided volume\>125mL, TPV\<40                                                                                                                                                                                                                                                     

  252                           213                                              65.1              64.8                                                                                                                         AUA8-35, Qmax4-15mL/s, voided volume\>125mL, TPV\>40                                                                                                                                                                                                                                                     

  Kaplan                        The Journal of Urology                           2008              USA                                                                                                                          768                                                    737              62.6                       62.5   Qmax 4-15mL/s, voided volume\>125mL, AUA-SI score 8--30                                                                               0   0   0   Finasteride                       5          54

  Bepple                        UROLOGY                                          2009              USA                                                                                                                          30                                                     29               66                         66     NA                                                                                                                                    0   0   0   Dutasteride                       0.5        12

  Tsukamoto                     Hinyokika Kiyo                                   2009              Japan                                                                                                                        70                                                     70               66.1                       65.8   Qmax\>15mL/s, IPSS\>3                                                                                                                 0   0   0   Dutasteride                       0.5        6

  Tsukamoto                     International Journal of Urology                 2009              Japan                                                                                                                        193                                                    185              67.7                       64.4   Qmax\<15mLs, IPSS≥8, voided volume≥150mL, PV\>30mL                                                                                    1   0   0   Dutasteride                       0.5        13

  Tsukamoto                     Hinyokika Kiyo                                   2010              Japan                                                                                                                        184                                                    181              68                         66.9   Qmax\<15mLs, IPSS≥8, PV\<30cc                                                                                                         1   0   0   Dutasteride                       0.5        13

  Kaplan                        The Journal of Urology                           2011              USA                                                                                                                          281                                                    276              60.7                       60.3   Qmax 4-15mL/s, AUA-SI score 8--30 voided volume\>125mL, PV\<30mL                                                                      0   0   0   Finasteride                       5          54

  295                           288                                              63.9              64.1                                                                                                                         Qmax4-15mL/s, AUA-SI score 8--30\                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                voided volume\>125mL, PV\>30mL                                                                                                                                                                                                                                                                           

  Roehrborn                     UROLOGY                                          2011              USA                                                                                                                          4049                                                   4073             62.7                       62.7   50--60 years old: PSA2.5-10ng/mL, \>60 years old: 3.0-10ng/mL                                                                         1   0   0   Dutasteride                       0.5        48

  Yanqun                        Clinical Drug Investigation                      2012              China                                                                                                                        126                                                    127              65.8                       66.9   Qmax 5-15mL/s, AUA-SI score\>12\                                                                                                      1   0   0   Dutasteride                       0.5        6
                                                                                                                                                                                                                                                                                                                                          voided volume\>125mL,                                                                                                                                                                          

  Kacker                        Androlodia                                       2015              USA                                                                                                                          11                                                     11               57.7                       57.7   Testosterone (T) for at least 3 months, and a current serum T within the normal range (300--1000ng dl)                                0   0   0   Dutasteride                       0.5        12

  Qian                          The Aging Male                                   2015              China                                                                                                                        45                                                     42               70.1                       72.3   PV\>80mL, IPSS≥13, QoL≥3, PVR200mL, Qmax\<15mL/s, refractory HU history, bladder stone history, AUR history, refractory UTI history   1   0   0   5ARI Finasteride or Dutasteride   5 or 0.5   6
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA, not available; BPH, benign prostatic hyperplasia; 5ARI, 5 alpha reductase inhibitor; PVR, post voided residual volume; PSA, prostatic specific antigen; PV, prostatic volume; IPSS, International Prostate Symptom Score; Qmax, maximal urinary flow rate; QoL, quality of life. UTI, urinary tract infection

Risk of bias {#sec013}
------------

For random sequence generation, most of the included studies showed a low risk and only a single study showed unclear risk ([S1 Table](#pone.0203479.s004){ref-type="supplementary-material"}). For allocation concealment, 28 studies showed unclear risk and 14 studies showed low risk. For blinding of participants and personnel (performance bias), 7 studies showed high risk, one study showed unclear risk and 34 studies showed low risk.

Effective size of PSA, PV, IPSS, and Qmax of 5ARI compared with placebo {#sec014}
-----------------------------------------------------------------------

For PSA, a total of 13 studies were included in the meta-analysis. The overall effective size based on SMD was -0.76 (95% CI, -1.31, -0.22)([S1 Fig](#pone.0203479.s006){ref-type="supplementary-material"}), which showed a significant decrease in PSA level after 5ARI treatment compared with placebo. The overall effective size showed moderate effect of improvement by Cohen's cutoff. The overall effective size based on WMD was -1.27 (-2.29, -0.24). For PV, a total of 26 studies were included in the meta-analysis. The overall effective size based on SMD was -0.63 (95% CI, -0.74, -0.52)([S2 Fig](#pone.0203479.s007){ref-type="supplementary-material"}), which showed a significant decrease of PV after 5ARI medication compared with placebo. The overall effective size showed moderate effect of improvement by Cohen's cutoff. The overall effective size based on WMD was -11.13 (-13.34, -8.93). For PVR, a total of 5 studies were included in the meta-analysis. The overall effective size by SMD was 0.1 (95% CI, -0.48, 0.68), which showed insignificant decrease of PVR after 5ARI treatment compared with placebo. For IPSS, a total of 18 studies were included in the meta-analysis. The overall effective size by SMD was -0.19 (95% CI, -0.27, -0.11)([Fig 2](#pone.0203479.g002){ref-type="fig"}), which showed a significant decrease of IPSS after 5ARI intervention compared with placebo. The overall effective size showed small effect of improvement by Cohen's cutoff. The overall effective size based on WMD was -1.21(-1.72, -0.70). Finasteride showed a significant improvement of IPSS as -0.18 (95% CI, -0.26, -0.10). However, dutasteride showed no significant improvement in IPSS as -0.21 (95% CI, -0.42, 0.00). For Qmax, a total of 23 studies were included in the meta-analysis, and the overall effective size by SMD was 0.29 (95% CI, 0.22 to 0.36)([S3 Fig](#pone.0203479.s008){ref-type="supplementary-material"}), which showed significant improvement of Qmax after 5ARI treatment compared with placebo. The overall effective size based on WMD was -1.16 (0.88, 1.43).

![Meta-analysis of effective sizes in prostate specific antigen (PSA), International Prostate Symptom Score (IPSS), prostate volume and maxima urinary flow rate (Qmax).](pone.0203479.g002){#pone.0203479.g002}

Cumulative analysis {#sec015}
-------------------

Cumulative meta-analysis was performed to investigate the trend according to years. For PSA, in 1990s, effective size showed no significant difference compared with placebo. However, starting with 2000s, the effective size showed a significant difference compared with placebo, resulting in a stable outcome from -0.77 to -0.60. For PV, the effect size showed a constant and significant difference compared with placebo, which showed stable outcome from -0.70 to -0.40 ([Fig 3A](#pone.0203479.g003){ref-type="fig"}). For IPSS, there was no marked change in the trend of effective size compared with placebo, however, the effective size of difference compared with placebo showed a decreasing trend ([Fig 3B](#pone.0203479.g003){ref-type="fig"}). For Qmax, the effective size showed a large difference compared with placebo until 1993. However, from 1994, the effective size of difference showed a decreasing trend as a convergence of 0.3 ([Fig 3C](#pone.0203479.g003){ref-type="fig"}).

![Cumulative analysis of effective sizes in prostate volume, International Prostate Symptom Score (IPSS), and maxima urinary flow rate (Qmax).](pone.0203479.g003){#pone.0203479.g003}

Sensitivity analysis {#sec016}
--------------------

Considering the relatively high heterogeneity, sensitivity analysis was performed to analyze the effect of each study. Overall effect size of all variables except PVR showed no impact of individual studies ([S4 Fig](#pone.0203479.s009){ref-type="supplementary-material"}). However, the effect size of PVR was affected by one study, which resulted in a different outcome without that study.

Meta-regression {#sec017}
---------------

To investigate the reasons for heterogeneity of effect, a meta-regression analysis was performed. Moderating factor was suggested as IPSS at baseline, follow-up duration and race. Effective sizes of all variables except PVR showed no significant moderating effect. However, the effective size of PVR was affected by IPSS at baseline. The effective size of PVR decreased according to high IPSS at the baseline: -0.29 (95% CI, -0.46,-0.12) in univariate analysis. Multivariable analysis was not performed due to the small number of included studies.

ROM analysis of placebo group {#sec018}
-----------------------------

To show the placebo effect of each variable, a ROM analysis was performed ([Table 2](#pone.0203479.t002){ref-type="table"}). For PSA, although it did not show a significant effective size, it still showed a decrease by 10% (0.90 (95% CI, 0.81, 1.00) during follow-up. For PV, there was no change during follow-up: 1.00 (95% CI, 0.88, 1.14). For IPSS, there was a significant decrease during follow-up: 0.77 (95% CI, 0.68, 0.88), suggesting a 23% improvement. For Qmax, there was significant increase during the follow-up: -1.13 (95% CI, 1.06, 1.20), suggesting a 13% aggravation.

10.1371/journal.pone.0203479.t002

###### Ratio of means meta-analysis of the efficacy of placebo group.

![](pone.0203479.t002){#pone.0203479.t002g}

  Author (year)              No. of samples   Ratio of mean (95% CI)[^a^](#t002fn002){ref-type="table-fn"}                                                                                   
  -------------------------- ---------------- -------------------------------------------------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Gormley (1992)             300                                                                             0.98 (0.89, 1.08)                       0.90 (0.81, 0.99)   0.88 (0.80, 0.97)   1.02 (0.96, 1.08)
  Kirby (1992)               10               0.80 (0.39, 1.64)                                              0.96 (0.49, 1.87)   0.52 (0.16, 1.64)   0.81 (0.48, 1.39)                       0.90 (0.54, 1.51)
  Tempany (1993)             8                                                                               1.01 (0.63, 1.62)                                                               
  Tammela (1993)             17                                                                                                  1.10 (0.64, 1.88)                                           1.12 (0.90, 1.41)
  Andersen (1995)            197                                                                             1.28 (1.04, 1.56)                       1.02 (0.93, 1.11)   0.98 (0.90, 1.06)   0.97 (0.93, 1.02)
  Tammela (1995)             15                                                                              0.96 (0.72, 1.27)   1.19 (0.63, 2.24)                                           1.11 (0.87, 1.42)
  Yu (1995)                  22               0.89 (0.51, 1.58)                                              1.06 (0.83, 1.37)                       0.86 (0.73, 1.01)                       1.01 (0.80, 1.29)
  Habib (1997)                                1.26 (0.77, 2.05)                                                                                                                              
  Lepor (1998)               258                                                                             1.01 (0.94, 1.09)                       0.84 (0.79, 0.89)                       1.13 (1.08, 1.20)
  Marberger (1998)           800                                                                             1.04 (0.99, 1.09)                                                               
  Pannek (1998)              10               0.73 (0.28, 1.88)                                              0.97 (0.69, 1.37)                                                               
  Abrams (1999)                                                                                                                                      0.82 (0.69, 0.96)                       0.99 (0.88, 1.11)
  Lukkarinen (1999)          31                                                                              0.92 (0.76, 1.10)                                                               0.84 (0.67, 1.06)
  Feneley (2000)             9                                                                               0.82 (0.52, 1.31)                                                               1.23 (0.85, 1.77)
  Isotalo (2001)             19               0.66 (0.53, 0.81)                                              0.91 (0.75, 1.11)                                                               1.09 (0.76, 1.56)
  Haggstrom (2002)                            1.02 (0.86, 1.21)                                                                                                                              
  Kirby (2003)                                1.12 (0.96, 1.29)                                                                                      0.69 (0.63, 0.74)                       1.12 (1.06, 1.18)
  McConnell (2003)                                                                                                                                   0.76 (0.73, 0.80)                       1.13 (1.10, 1.16)
  Roehrborn (2004)                            0.89 (0.84, 0.95)                                                                                      0.97 (0.94, 1.00)                       
  Crawford (2006)                                                                                                                                                                            1.13 (1.11, 1.16)
  Kaplan (2008)              249                                                                             1.34 (1.22, 1.46)                                                               
  Kaplan (2008)a             214                                                                             1.12 (1.04, 1.21)                                                               
  Kaplan (2008)b             112                                                                             1.20 (1.08, 1.32)                                                               
  Kaplan (2008)c             161                                                                             1.21 (1.16, 1.27)                                                               
  Tsukamoto (2009)           70                                                                              0.81 (0.69, 0.95)                       0.73 (0.62, 0.85)                       1.12 (0.99, 1.27)
  Qian (2015)                42               0.81 (0.77, 0.86)                                              0.60 (0.57, 0.63)   0.06 (0.05, 0.07)   0.36 (0.32, 0.41)                       2.79 (2.36, 3.30)
  Overall                                     0.90 (0.81, 1.00)                                              1.00 (0.88, 1.14)   0.44 (0.06, 3.22)   0.77 (0.68, 0.88)   0.93 (0.84, 1.03)   1.13 (1.06, 1.20)
                                              p = 0.056                                                      p = 0.97            p = 0.42            p\<0.001            p = 0.159           p\<0.001
  Heterogeneity---I^2^ (%)                    73.3 (47.8, 86.3)                                              96.3 (95.1, 97.1)   98.5 (97.6, 99.0)   96.7 (95.4, 97.6)   61.9 (0.0, 91.2)    91.3 (87.5, 93.9)
  p-value                    \<0.001          \<0.001                                                        \<0.001             \<0.001             0.105               \<0.001             

CI, confidence interval; PSA, prostate specific antigen; PV, prostate volume; PVR, post voided residual volume; IPSS, International Prostate Symptom Score; Qmax, maximal urinary flow rate.

^a^ The process of meta-analysis with paired difference data: estimates using the Hegde\'s corrected standardized mean difference assuming the random-effect model

Meta-regression of ROM analysis in placebo group {#sec019}
------------------------------------------------

To investigate the reasons for the placebo effect in ROM analysis, the published year and follow-up duration were suggested as moderators ([S2 Table](#pone.0203479.s005){ref-type="supplementary-material"}). For PSA, there was no significant moderator effect. However, for PV, IPSS, and Qmax, both published year and follow-up duration were significant moderators. The effective size of PV and IPSS was decreased according to years of recent publication (p\<0.001), and was increased according to follow-up duration (p\<0.001). In contrast, the effective size of Qmax was increased according to years of recent publication (p\<0.001), and decreased by the follow-up duration (p = 0.020). For PVR, only the year of publication affected the effective size, which showed a decreased effect according to the year of recent publication (p\<0.001).

Adverse events {#sec020}
--------------

The 5ARI treatment prevented exacerbation of BPH and urinary retention compared with placebo ([Table 3](#pone.0203479.t003){ref-type="table"}). However, compared with placebo, 5ARI showed a significantly higher incidence of decreased libido (OR = 1.7; 95% CI, 1.36, 2.13), ejaculatory disorder (OR = 2.94; 95% CI, 2.15, 4.03), gynecomastia (OR = 2.32; 95% CI, 1.41, 3.83), and impotence (OR = 1.74; 95% CI, 1.32, 2.29). Decreased libido and impotence was affected by the moderating effect of follow-up duration. After meta-regression of follow up duration, decreased libido (OR = 0.98, 95% CI, 0.97, 0.99) and increased impotence (OR = 0.98, 95% CI, 0.97, 0.99) were significantly related to longer follow-up duration.

10.1371/journal.pone.0203479.t003

###### Meta-analysis and meta-regression of effective sizes in adverse events.

![](pone.0203479.t003){#pone.0203479.t003g}

  Complication                             Effect size           Meta-regression on f/u duration (month)                               
  ---------------------------------------- --------------------- ----------------------------------------- ------- ------------------- -------
  Abdominal pain                           1.16 (0.78--1.74)     0.455                                     0.0%    0.97 (0.91--1.04)   0.377
      Gormley (1992)                       3.37 (0.32--35.31)    0.311                                                                 
      Marberger (1998)                     1.06 (0.68--1.67)     0.784                                                                 
      Stoner (1994)                        1.7 (0.41--7.09)      0.464                                                                 
      Tsukamoto (2009)                     0.14 (0.01--2.62)     0.186                                                                 
      Tsukamoto (2009)                     2.03 (0.53--7.8)      0.303                                                                 
  Angina pectoris                          1.01 (0.55--1.84)     0.977                                     NA%     NA                  NA
      Marberger (1998)                     1.01 (0.55--1.84)     0.977                                                                 
  Any AE                                   0.98 (0.88--1.09)     0.767                                     56.8%   1.01 (0.99--1.03)   0.368
      Andersen (1995)                      1.3 (0.83--2.05)      0.251                                                                 
      Beisland (1992)                      1 (0.75--1.33)        0.992                                                                 
      Kacker (2015)                        NA (NA-NA)            NA                                                                    
      Nickel (1996)                        1 (0.93--1.08)        0.922                                                                 
      The finasteride study group (1993)   12.44 (1.63--94.95)   0.015                                                                 
      Tsukamoto (2009)                     0.98 (0.91--1.05)     0.505                                                                 
      Tsukamoto (2009)                     0.83 (0.67--1.03)     0.09                                                                  
  Asthenia                                 0.86 (0.59--1.25)     0.43                                      2.5%    0.93 (0.87--1)      0.046
      Gormley (1992)                       1.01 (0.21--4.96)     0.99                                                                  
      Kirby (2003)                         1.02 (0.45--2.31)     0.964                                                                 
      Lepor (1996)                         1.08 (0.61--1.91)     0.797                                                                 
      Marberger (1998)                     0.46 (0.23--0.94)     0.033                                                                 
      Stoner (1994)                        1.28 (0.34--4.73)     0.714                                                                 
  Back pain                                0.61 (0.39--0.95)     0.028                                     0.0%    NA                  NA
      Marberger (1998)                     0.59 (0.37--0.95)     0.029                                                                 
      Tsukamoto (2009)                     0.76 (0.18--3.28)     0.713                                                                 
  BPH worsening                            0.55 (0.37--0.83)     0.004                                     NA%     NA                  NA
      Marberger (1998)                     0.55 (0.37--0.83)     0.004                                                                 
  Breast pain                              2.49 (0.88--7.01)     0.084                                     0.0%    NA                  NA
      Gormley (1992)                       3.03 (0.12--74.09)    0.497                                                                 
      McConnell (1998)                     2.43 (0.81--7.26)     0.112                                                                 
  Bronchitis                               1.15 (0.7--1.91)      0.579                                     NA%     NA                  NA
      Marberger (1998)                     1.15 (0.7--1.91)      0.579                                                                 
  Decreased libido                         1.67 (1.35--2.06)     \<0.001                                   9.8%    0.98 (0.97--0.99)   0.004
      Bepple (2009)                        6.53 (0.35--120.66)   0.208                                                                 
      Gormley (1992)                       3.63 (1.19--11.01)    0.023                                                                 
      Kirby (2003)                         1.83 (0.62--5.4)      0.271                                                                 
      Lepor (1996)                         3.44 (1.15--10.34)    0.028                                                                 
      Marberger (1998)                     1.44 (0.99--2.11)     0.057                                                                 
      McConnell (1998)                     1.01 (0.65--1.56)     0.965                                                                 
      Nickel (1996)                        1.59 (0.92--2.76)     0.095                                                                 
      Roehrborn (2002)                     1.97 (1.39--2.79)     \<0.001                                                               
      Stoner (1994)                        2.04 (0.93--4.51)     0.077                                                                 
      Tsukamoto (2009)                     4.77 (0.23--98.64)    0.312                                                                 
      Yanqun (2012)                        2.02 (0.19--21.95)    0.565                                                                 
      Yu (1995)                            4.59 (0.23--90.58)    0.316                                                                 
  Diarrhea                                 1.05 (0.58--1.9)      0.863                                     0.0%    NA                  NA
      Gormley (1992)                       NA (NA-NA)            NA                                                                    
      Marberger (1998)                     1.15 (0.56--2.35)     0.696                                                                 
      Tsukamoto (2009)                     0.87 (0.31--2.46)     0.792                                                                 
  Dizziness                                1.06 (0.74--1.52)     0.754                                     0.0%    1.09 (0.88--1.34)   0.451
      Gormley (1992)                       0.19 (0.01--3.99)     0.288                                                                 
      Kirby (2003)                         1.07 (0.59--1.93)     0.822                                                                 
      Lepor (1996)                         1.16 (0.67--2.01)     0.588                                                                 
      Stoner (1994)                        1.02 (0.26--4.07)     0.975                                                                 
      Tsukamoto (2009)                     4.77 (0.23--98.64)    0.312                                                                 
      Tsukamoto (2009)                     0.68 (0.2--2.29)      0.53                                                                  
  Dyspepsia                                0.34 (0.01--8.16)     0.504                                     NA%     NA                  NA
      Tsukamoto (2009)                     0.34 (0.01--8.16)     0.504                                                                 
  Dysuria                                  1.34 (0.66--2.72)     0.417                                     0.0%    NA                  NA
      Gormley (1992)                       5.05 (0.24--104.75)   0.295                                                                 
      Marberger (1998)                     1.24 (0.6--2.57)      0.56                                                                  
  Ejaculatory disorder                     2.89 (2.12--3.93)     \<0.001                                   0.0%    1 (0.98--1.03)      0.689
      Gormley (1992)                       2.57 (0.94--7.08)     0.067                                                                 
      Kirby (2003)                         1.53 (0.44--5.35)     0.507                                                                 
      Lepor (1996)                         1.48 (0.42--5.18)     0.543                                                                 
      Marberger (1998)                     3.7 (1.78--7.7)       \<0.001                                                               
      McConnell (1998)                     3.01 (1.33--6.81)     0.008                                                                 
      McConnell (1998)                     1.99 (0.28--14.11)    0.491                                                                 
      Nickel (1996)                        4.69 (1.81--12.14)    0.001                                                                 
      Roehrborn (2002)                     2.81 (1.62--4.87)     \<0.001                                                               
      Tsukamoto (2009)                     4.06 (0.46--35.41)    0.205                                                                 
  Erectile dysfunction                     1.51 (0.15--15.27)    0.725                                     34.1%   NA                  NA
      Tsukamoto (2009)                     3.81 (0.43--33.8)     0.229                                                                 
      Yanqun (2012)                        0.34 (0.01--8.17)     0.503                                                                 
  Flatulence                               1.39 (0.45--4.34)     0.568                                     0.0%    NA                  NA
      Gormley (1992)                       1.44 (0.25--8.36)     0.682                                                                 
      Stoner (1994)                        1.36 (0.31--6.04)     0.687                                                                 
  Gastritis                                1.3 (0.65--2.6)       0.463                                     NA%     NA                  NA
      Marberger (1998)                     1.3 (0.65--2.6)       0.463                                                                 
  Gynecomastia                             2.29 (1.4--3.76)      0.001                                     19.9%   0.98 (0.95--1.01)   0.119
      McConnell (1998)                     1.61 (0.88--2.95)     0.124                                                                 
      Roehrborn (2002)                     3.11 (1.78--5.45)     \<0.001                                                               
      Yanqun (2012)                        3.02 (0.12--73.53)    0.497                                                                 
  Headache                                 0.97 (0.62--1.52)     0.906                                     38.0%   0.96 (0.91--1.01)   0.137
      Beisland (1992)                      1.4 (0.52--3.78)      0.502                                                                 
      Gormley (1992)                       0.96 (0.14--6.63)     0.969                                                                 
      Lepor (1996)                         1.87 (0.88--3.95)     0.102                                                                 
      Marberger (1998)                     0.92 (0.58--1.48)     0.743                                                                 
      Marberger (1998)                     0.42 (0.2--0.88)      0.021                                                                 
      Stoner (1994)                        1.7 (0.41--7.09)      0.464                                                                 
      Tsukamoto (2009)                     0.51 (0.1--2.68)      0.424                                                                 
  Hypertension                             0.82 (0.58--1.14)     0.239                                     0.0%    NA                  NA
      Kirby (2003)                         0.75 (0.35--1.6)      0.452                                                                 
      Marberger (1998)                     0.83 (0.57--1.22)     0.347                                                                 
  Hypotension                              0.51 (0.09--2.76)     0.434                                     NA%     NA                  NA
      Kirby (2003)                         0.51 (0.09--2.76)     0.434                                                                 
  Impotence                                1.68 (1.3--2.17)      \<0.001                                   58.1%   0.98 (0.97--0.99)   0.001
      Gormley (1992)                       1.98 (0.69--5.68)     0.204                                                                 
      Kirby (2003)                         1.47 (0.64--3.38)     0.363                                                                 
      Lepor (1996)                         2.04 (1.1--3.78)      0.024                                                                 
      Marberger (1998)                     1.42 (1.06--1.89)     0.018                                                                 
      McConnell (1998)                     1 (0.74--1.36)        0.981                                                                 
      Nickel (1996)                        2.52 (1.52--4.18)     \<0.001                                                               
      Roehrborn (2002)                     1.83 (1.42--2.36)     \<0.001                                                               
      Stoner (1994)                        3.07 (1.31--7.15)     0.01                                                                  
  Influenza                                0.89 (0.58--1.37)     0.602                                     NA%     NA                  NA
      Marberger (1998)                     0.89 (0.58--1.37)     0.602                                                                 
  Lens change                              1.2 (0.3--4.81)       0.793                                     12.7%   NA                  NA
      Gormley (1992)                       5.05 (0.24--104.75)   0.295                                                                 
      Gormley (1992)                       0.19 (0.01--3.99)     0.288                                                                 
      Stoner (1994)                        1.36 (0.31--6.06)     0.684                                                                 
  Myocardial infarction                    2.9 (1.3--6.46)       0.009                                     NA%     NA                  NA
      Marberger (1998)                     2.9 (1.3--6.46)       0.009                                                                 
  Nausea                                   0.73 (0.23--2.28)     0.582                                     0.0%    NA                  NA
      Gormley (1992)                       0.67 (0.11--4)        0.664                                                                 
      Stoner (1994)                        0.76 (0.17--3.4)      0.724                                                                 
  orgasm dysfunction                       0.8 (0.08--8.3)       0.85                                      31.3%   NA                  NA
      Gormley (1992)                       2.24 (0.19--26.87)    0.523                                                                 
      Stoner (1994)                        0.2 (0.01--4.25)      0.305                                                                 
  Pelvic pain                              0.48 (0.04--5.18)     0.546                                     NA%     NA                  NA
      Gormley (1992)                       0.48 (0.04--5.18)     0.546                                                                 
  Pharyngitis                              1.6 (0.78--3.28)      0.202                                     NA%     NA                  NA
      Marberger (1998)                     1.6 (0.78--3.28)      0.202                                                                 
  Postural hypotension                     1.18 (0.27--5.12)     0.821                                     46.5%   NA                  NA
      Kirby (2003)                         0.51 (0.09--2.76)     0.434                                                                 
      Lepor (1996)                         2.3 (0.6--8.8)        0.225                                                                 
  Rash                                     1.59 (0.63--4.01)     0.326                                     38.4%   1.03 (0.97--1.09)   0.39
      Gormley (1992)                       2.24 (0.19--26.87)    0.523                                                                 
      Marberger (1998)                     0.82 (0.43--1.54)     0.532                                                                 
      McConnell (1998)                     5.31 (0.93--30.3)     0.061                                                                 
      Stoner (1994)                        2.04 (0.38--11.11)    0.408                                                                 
  Rhinitis                                 0.56 (0.24--1.32)     0.186                                     NA%     NA                  NA
      Lepor (1996)                         0.56 (0.24--1.32)     0.186                                                                 
  Sinusitis                                0.98 (0.25--3.9)      0.982                                     NA%     NA                  NA
      Lepor (1996)                         0.98 (0.25--3.9)      0.982                                                                 
  Somnolence                               1.36 (0.48--3.86)     0.565                                     NA%     NA                  NA
      Kirby (2003)                         1.36 (0.48--3.86)     0.565                                                                 
  Syncope                                  1.63 (0.08--31.47)    0.747                                     46.0%   NA                  NA
      Kirby (2003)                         0.34 (0.01--8.3)      0.508                                                                 
      Lepor (1996)                         6.89 (0.36--132.77)   0.201                                                                 
  Testicular pain                          1.4 (0.45--4.35)      0.565                                     0.0%    NA                  NA
      Gormley (1992)                       1.44 (0.25--8.36)     0.682                                                                 
      Stoner (1994)                        1.36 (0.31--6.06)     0.684                                                                 
  upper respiratory infection              0.7 (0.41--1.19)      0.191                                     NA%     NA                  NA
      Marberger (1998)                     0.7 (0.41--1.19)      0.191                                                                 
  urinary retention                        0.49 (0.28--0.87)     0.015                                     NA%     NA                  NA
      Marberger (1998)                     0.49 (0.28--0.87)     0.015                                                                 
  Urinary tract Infection                  0.71 (0.44--1.14)     0.154                                     NA%     NA                  NA
      Marberger (1998)                     0.71 (0.44--1.14)     0.154                                                                 
  Vertigo                                  2.04 (0.52--8.06)     0.31                                      NA%     NA                  NA
      Kirby (2003)                         2.04 (0.52--8.06)     0.31                                                                  

OR, odds ratio; CI, confidence interval.

Publication bias {#sec021}
----------------

There was no publication bias detected following Egger's test ([S5 Fig](#pone.0203479.s010){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

Although current guidelines suggest the use of 5ARI in patients with prostate size greater than 30cc, our study does not support the wide use of 5ARI, rather it needs specific indication. Although there has been a systematic review about this issue, especially for finasteride \[[@pone.0203479.ref011]\], it needs to be upgraded. The main academic basic hypothesis of our study is based on the most recent focus on androgens in aged men. It is well known that androgens profoundly regulate prostate growth and differentiation, as well as sexual function \[[@pone.0203479.ref012], [@pone.0203479.ref018]\]. However, it is also associated with general health of aged men including cardiovascular disease. A recent RCT showed that a 1-year treatment of testosterone showed superior outcomes compared with placebo in coronary artery non-calcified plaque volume \[[@pone.0203479.ref027]\]. In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, the dutasteride treatment group showed larger rate of cardiac failure compared with placebo \[[@pone.0203479.ref028]\]. Moreover, the 5ARI treatment was again associated with the possible risk of suicidal attempts and depression in many observational studies \[[@pone.0203479.ref020]\].

It is beyond dispute that the combination treatment of alpha-blocker and 5ARI is superior to alpha-blocker monotherapy or placebo group \[[@pone.0203479.ref005], [@pone.0203479.ref006]\]. In early trials, the effect of combination treatment was mainly attributed to alpha-blocker and also to the double-placebo effect. In MTOPS trial, the overall effect of two placebo combinations was -4.0 at 1 year and also -4.0 at 4 years, which suggests a 23.8% improvement in placebo effect \[[@pone.0203479.ref005]\]. Further, at 1 year, there was no significant difference in symptom improvement between the alpha-blocker and combination groups \[[@pone.0203479.ref005]\]. Due to the absence of meta-analysis involving alpha-blocker, 5ARI, and placebo, this study failed to confirm the poor clinical efficacy of 5ARI compared with alpha-blockers. However, this is the first meta-analysis investigating the clinical efficacy of 5ARI monotherapy among RCTs, which showed that overall effective size of IPSS improvement by 5ARI compared with placebo was small. Moreover, the overall effective size of PV and PSA was moderate.

For PV growth, previous studies reported an annual growth rate of 0.6 cc per year (−9.9\~11.8) \[[@pone.0203479.ref029]\]. Interestingly, the negative PV growth rate represents the diversity of growth rate according to individual characteristics. Loeb et al \[[@pone.0203479.ref030]\] reported that a considerable proportion of aging men do not show progressive PV enlargement, and a few manifested decreasing pattern. In their study of median follow up of 4.3 years, a progressive PV growth was noted in 61.9%. However, 38.1% of men showed no increase or decrease in PV with the rate of PV changing by 0.6cc annually (-9.9\~62.1). They speculated that aging could induce prostate shrinkage in healthy community men due to genetic, hormonal or environmental factors. In another study of Olmsted county survey, the median growth rate of PV was 1.9% per year \[[@pone.0203479.ref031]\]. In our study, it was not logical to estimate the annual grow rate because this study does not contain direct population data. However, this study demonstrated the changes of PV in placebo group, which suggested that the PV growth rate was 1.00 by ROM (95% CI, 0.88--1.14), which showed lack of increase in PV size during the years of investigation of enrolled studies.

For adverse events, two recent reviews reported adverse effects including ED, decreased libido, gynecomastia, and anxiety following 5ARI therapy \[[@pone.0203479.ref018], [@pone.0203479.ref019]\]. Our study also found similar adverse effects including decreased libido, ejaculatory disorder, gynecomastia and impotence. Interestingly, Corona et al \[[@pone.0203479.ref018]\] reported that adverse events were inversely correlated with study duration. Our study also showed similar findings of decreased libido and impotence affected by the moderating effect of follow-up duration, which showed attenuation of decreased libido and impotence during a longer follow-up. Further studies are needed by merging data of 5ARI studies with other indications such as alopecia. Moreover, comorbidity status should be taken into account when considering the incidence of ED in patients receiving 5-ARIs. 5-ARIs are often prescribed to older patients with high comorbidity status, which could also increase the risk of ED \[[@pone.0203479.ref032]\]. The comorbidity status is often underreported in published studies and this may represent a bias.

The detailed mechanism underlying the negative impact of 5ARI on ED or decreased libido has not been fully demonstrated. Several suggested theories include: 1) Decrease synthesis of neurostransmitters by 5ARI \[[@pone.0203479.ref013]\], which is related to sexual desire; 2) 5ARIs induce structural and functional degeneration of penile tissue, which results in penile fibrosis due to cholinergic and nitrergic sensitivity \[[@pone.0203479.ref013]\]. In animal studies, finasteride suppressed neurosteroid synthesis, which resulted in anxiety and depression \[[@pone.0203479.ref033]--[@pone.0203479.ref035]\], which could explain the possible association between 5ARI treatment and depression or suicidal attempts.

Our study is academically sound and robust due to several reasons: 1) It is the first scientific review including meta-analysis of RCTs investigating the efficacy and adverse events associated with 5ARI monotherapy; 2) It shows an indirect effect of the reported years using a cumulative meta-analysis; 3) It shows indirect outcomes of prostate growth using a single-placebo-controlled meta-analysis. In our study, although the effective size of PSA, IPSS, PV, and Qmax showed significantly superior outcome compared with the placebo group, the effective size, especially for IPSS (-0.19, 95%CI: -0.27- -0.11) was small. Considering the effective size was analyzed by SMD, it could be interpreted as 7.5% by two sided test and as 15% by one sided test. By subgroups, although finasteride showed a significant improvement of IPSS, dutasteride showed not significant improvement, which is due to relatively lower published studies of dutasteride than finasteride. The included studies showed a lower clinical improvement in IPSS, PV and Qmax when recent publications were considered. PV showed a relatively slower growth than in previous clinical studies.

Due to limitation of meta-analysis, detailed individual level data could not be extracted. Furthermore, we could not find a long term complication including depression and suicidal attack, which could not be reported in ITT study design. For those complications, observational studies have to be included. This study also included outdated studies which only have focused on finasteride, which could result in favorable effect of finasteride than dutasteride during meta-analysis. One more crucial limitation in our study is that several studies among final included studies for meta-analysis do not have clinically significant BOO, which could resulted in lowering efficacy of 5ARI during meta-analysis. Moreover, recent meta-analysis about the efficacy of 5ARI in BOO has showed that BOOI reduction is important clinical outcomes during BPH/LUTS treatment \[[@pone.0203479.ref010]\]. Lastly, network analysis among alpha blocker, 5ARI, and placebo are needed to suggest the direct evidence of inferior clinical efficacy of 5ARI compared to alpha blocker.

In future, the accurate prevalence rate of persistent adverse events after 5ARI discontinuation needs to be investigated. Moreover, considering the long-term clinical efficacy of 5ARI, long-term adverse events need to be investigated more clearly. This meta-analysis provides useful information for clinicians and clinical investigators to design controlled studies investigating long-term outcomes following 5ARI therapy.

Conclusions {#sec023}
===========

In this meta-analysis with an average follow-up duration of 21.8 months, the efficacy outcomes of 5ARI showed a small clinical improvement in improvement of LUTS. In future, well designed studies are needed to overcome placebo effect and heterogeneities and possible bias. Considering persistent and well known adverse events including ED and decreased libido even after discontinuation of 5ARI, 5ARI therapy should be prescribed with great caution and patients need to be fully informed about the possible adverse events. A more selective rationale is needed considering the diverse growth rate of PV, and a relatively low growth rate observed in our study.
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